Musculoskeletal Diseases clinical trials at UC Irvine

1 in progress, 0 open to eligible people

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping
Sorry, not accepting new patients
The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Irvine, California and other locations

Last updated: July 15, 2026

Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping